FDA clears Meridian's Curian Campy assay

By LabPulse.com staff writers

January 6, 2022 -- Meridian Bioscience has received U.S. Food and Drug Administration (FDA) clearance for its Curian Campy assay, a rapid, qualitative, fluorescent immunoassay for the detection of a campylobacter-specific antigen.

The assay was developed for use on the Curian immunofluorescent testing platform and was designed to detect campylobacter-specific antigen, including Campylobacter jejunii, C. coli, C. upsaliensis, and C. lari in human fecal specimens, Meridian said.

The Curian Campy assay features an easy workflow and produces objective results in about 20 minutes, the company said.

Curian Campy is the second FDA-cleared assay on Meridian's Curian testing platform. The Curian Analyzer and Curian HpSA assay received clearance in March 2020.

Meridian launches new master mixes
Meridian Bioscience has launched two new master mixes that enable direct detection of DNA or RNA/DNA from urine samples.
Meridian acquires GenePOC from Debiopharm
Meridian Bioscience is acquiring the GenePOC infectious disease-specialized molecular diagnostics business from Debiopharm, the companies announced on...

Copyright © 2022 LabPulse.com

Last Updated ls 1/6/2022 12:58:20 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current